Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Barst

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Heart (British Cardiac Society)|October 1, 1996
Quantitative three dimensional echocardiography in patients with pulmonary hypertension and compressed left ventricles: comparison with cross sectional echocardiography and magnetic resonance imagingH D Apfel, Z Shen, A S Gopal, et al.
The European Respiratory Journal|March 2, 2006
A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertensionI M Robbins, S M Kawut, D Yung, et al.
The European Respiratory Journal|October 3, 2002
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivativesM Humbert, Z Deng, G Simonneau, et al.
Clinical Pharmacology and Therapeutics|December 17, 2009
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertensionM Gomberg-Maitland, M L Maitland, R J Barst, et al.
Annals of Internal Medicine|September 1, 1991
Survival in patients with primary pulmonary hypertension. Results from a national prospective registryG E D'Alonzo, R J Barst, S M Ayres, et al.
American Journal of Human Genetics|July 25, 2000
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II geneZ Deng, J H Morse, S L Slager, et al.
Vascular Pharmacology|May 14, 2005
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effectAdaani E Frost, D Langleben, R Oudiz, et al.
International Journal of Cardiology|November 20, 2015
Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension)M Beghetti, I Schulze-Neick, R M F Berger, et al.
Circulation|June 29, 1999
Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertensionD Langleben, R J Barst, D Badesch, et al.
The New England Journal of Medicine|February 1, 1996
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertensionR J Barst, L J Rubin, W A Long, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Heart (British Cardiac Society)|October 1, 1996
Quantitative three dimensional echocardiography in patients with pulmonary hypertension and compressed left ventricles: comparison with cross sectional echocardiography and magnetic resonance imagingH D Apfel, Z Shen, A S Gopal, et al.
The European Respiratory Journal|March 2, 2006
A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertensionI M Robbins, S M Kawut, D Yung, et al.
The European Respiratory Journal|October 3, 2002
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivativesM Humbert, Z Deng, G Simonneau, et al.
Clinical Pharmacology and Therapeutics|December 17, 2009
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertensionM Gomberg-Maitland, M L Maitland, R J Barst, et al.
Annals of Internal Medicine|September 1, 1991
Survival in patients with primary pulmonary hypertension. Results from a national prospective registryG E D'Alonzo, R J Barst, S M Ayres, et al.
American Journal of Human Genetics|July 25, 2000
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II geneZ Deng, J H Morse, S L Slager, et al.
Vascular Pharmacology|May 14, 2005
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effectAdaani E Frost, D Langleben, R Oudiz, et al.
International Journal of Cardiology|November 20, 2015
Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension)M Beghetti, I Schulze-Neick, R M F Berger, et al.
Circulation|June 29, 1999
Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertensionD Langleben, R J Barst, D Badesch, et al.
The New England Journal of Medicine|February 1, 1996
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertensionR J Barst, L J Rubin, W A Long, et al.
Pageof 8